pharmaphorum

AUGUST 2, 2022

Antibody-drug conjugates are coming back to the fore, with talks of multi-billion dollar buyouts and a rapidly growing number of approvals. Antibody-drug conjugates (ADCs) are a class of biologic drugs designed for targeted treatment of cancer. billion in revenue last year. billion in revenue last year.

Marketing 97

Marketing Antibody Drugs Clinical Trials 97

pharmaphorum

FEBRUARY 14, 2022

The easy answer as to why this has happened can be quickly linked to the COVID-19 pandemic, where sales of vaccines and treatments led to a large increase in return on investment and sales projections. As a result, the estimated peak sales of assets increased from $360 million to $521 million in 2019 and 2021, respectively.

Production 98

Production Clinical Trials Clinical Trials Sales 98

pharmaphorum

DECEMBER 21, 2020

Each programme includes undisclosed upfront and milestone payments plus royalties on sales, with Merck indicating in a statement that it will be funding the research. billion alliance with Taiho and Astex for cancer antibodies, including a KRAS drug, and a $4.2 Other recent deals include a $2.8 Other recent deals include a $2.8

Immune Response 53

Immune Response Sales Antibody Pharma Companies 53

pharmaphorum

JUNE 2, 2021

The deal gives Amgen rights to the KHK4083 antibody in all countries except Kyowa’s home market of Japan, and is back-loaded with potential milestone payments worth another $850 million plus royalties on sales. Kyowa will co-promote the drug in the US if approved, with opt-in rights in some other countries as well.

Drugs 52

Drugs Licensing Licensing Sales 52

pharmaphorum

JANUARY 29, 2021

The Japanese pharma is in line for another $210 million if the drug reaches development and regulatory objectives, plus up to $210 million if it meets sales targets. While tanezumab is an antibody and has to be delivered by subcutaneous injection, AK1780 is orally bioavailable.

Licensing 52

Licensing Licensing Bioavailability Antibody 52

pharmaphorum

SEPTEMBER 21, 2021

Antibody-drug conjugate (ADC) specialist Seagen has claimed its fourth product approval in the US, getting the nod from the FDA for Tivdak as a second-line monotherapy for recurrent or metastatic cervical cancer. Seagen and Genmab are hosting a conference call later today to discuss further details of the new product.

Antibody 52

Antibody Pharma Companies Trials Drugs 52

pharmaphorum

SEPTEMBER 18, 2020

But although it was dubbed a “dangerous game”, some companies came out on top… On 6th April 1999, two companies with similar science-based cultures and a shared vision of the pharmaceutical industry came together to form what’s now considered as one of the top ten pharma companies in the world: AstraZeneca.

Pharma Companies 113

Pharma Companies Sales Vaccination Vaccine 113

XTalks

MAY 29, 2024

Here, we will deep-dive into the top five fastest growing pharma and biotech companies in 2024, showcasing their innovative strategies and inspiring achievements. Pfizer (Overall Rank 268) Leading the list is one of the most renowned pharma companies in the world: Pfizer.

Medicine 52

Medicine Marketing FDA Approval Development 52

pharmaphorum

FEBRUARY 14, 2022

Curevo joins other companies hoping to grab market share from Shingrix, which was dubbed the “crown jewel” of GSK’s vaccine franchise at the company’s latest R&D update and made $2.3 billion in sales last year, slightly down as a result of the pandemic.

Vaccination 52

Vaccination Vaccine Immune Response Trials 52

pharmaphorum

SEPTEMBER 20, 2022

Vaccines have transitioned from being a largely unloved area of the industry, with multiple big pharma companies divesting their vaccine divisions , to the biggest revenue drivers seen in recent years. Serum neutralising antibody increases were noted to be particularly high in subjects who had previously received an mRNA vaccine.

Vaccination 97

Vaccination Vaccine Immune Response Antibody 97

pharmaphorum

APRIL 7, 2021

While the Darzalex revenues are due to fall this year because of Janssen’s interpretation of the agreement between the two companies, there are also other revenue streams. With other drugs in the pipeline too, van de Winkel said the company aims to continue to break new ground with next-generation antibody-based therapies.

Antibody 71

Antibody Life Science Development Regulation 71

pharmaphorum

OCTOBER 10, 2021

Currently, ANCA vasculitis is treated with Roche’s antibody drug Rituxan (rituximab) combined with corticosteroids, which can have serious side effects when administered over prolonged periods. Other complement C5 inhibitors are available, notable AstraZeneca/Alexion’s injectable Soliris (eculizumab).

FDA Approval 52

FDA Approval Drugs Pharma Companies Clinical Trials 52

pharmaphorum

SEPTEMBER 17, 2021

Analysts have said that Lumakras could eventually make blockbuster sales of $1 billion or more, assuming Amgen can extend the label for the drug into the first-line NSCLC setting, as well as other KRAS-mutated tumour types. Boehringer alliance.

Trials 52

Trials Drugs Pharma Companies Clinical Trials 52

pharmaphorum

FEBRUARY 9, 2022

Closely related to this is the fact that global spending on oncology drugs reached $164 billion in 2020, with drug sales growing at a compound annual growth rate of 14.3% The oncology segment has been recognised as one of the most productive areas for pharmaceutical companies to focus their R&D investment. over the last five years.

Vaccination 131

Vaccination Vaccine Clinical Trials Clinical Trials 131

pharmaphorum

APRIL 28, 2022

Despite the inherent difficulties, major pharma companies do take aim at rare diseases, usually with dedicated units focusing on clusters of rare diseases that afflict the same part of the body. When a company, a big pharma company, calculates the financial impact, they also consider the sales force that they need, the marketing.

Pharma Companies 57

Pharma Companies Branding Development Marketing 57

pharmaphorum

SEPTEMBER 8, 2022

It is a similar approach to that of another form of oncology treatment that is also experiencing a surge of interest, antibody-drug conjugates (ADCs). billion acquisition of Endocyte in 2018 , with estimations that sales could reach $600 million in this first indication alone. The drug was added to Novartis’ portfolio through a $2.1

Manufacturing 102

Manufacturing Development Drugs Antibody 102

Drug Discovery World

OCTOBER 4, 2022

Oligomerix’s portfolio of compounds is expected to provide a potentially lower-cost treatment alternative and/or complement to the newly emerging high-cost therapeutic options such as the monoclonal antibody products. Several of the large pharma companies have recently re-entered the dementia field. With its recent award of $3.35

Development 52

Development In-Vivo Compound Screening Clinical Development 52

XTalks

MAY 25, 2021

Biosimilar and interchangeable products can expand treatment options and lower drug and healthcare costs by offering a cheaper alternative with the same effectiveness; essentially a non-branded version of a biologic such as monoclonal antibodies, proteins and vaccines. The deal will give AbbVie unspecified royalties on Amjevita sales.

Production 98

Production Drugs Marketing Sales 98

Drug Discovery World

OCTOBER 7, 2022

TH : Increasingly, large pharma companies need scale, agility and access to academic partnerships to succeed. It is unsurprising that many pharma companies are increasingly keen to work with academia or academic spin-out. companies to supplement their own R&D; most novel ideas stem from academia. Tony Hickson.

HR 52

HR Research Drugs Development 52

The Pharma Data

DECEMBER 17, 2020

Goater is CEO at Surface Oncology, an immuno-oncology company developing next-generation antibody therapies. AB2 Bio – Swiss pharma company AB2 Bio Ltd. Burger has held executive sales positions with two software-based medical device startups where he led commercialization strategy.

Development 52

Development Gene Therapy Engineer Life Science 52

XTalks

AUGUST 18, 2021

These samples are often made available to support the research efforts of pharma companies developing new antibacterial agents. Historically, the top 50 pharma companies by sales have been steadily ending their anti-infective, and in particular, their AMR drug development programs and have had little incentive to get back in the game.

Development 105

Development Bacteria Drugs Vaccination 105